Antipsychotic drug-like facilitation of latent inhibition by a brain-penetrating neurotensin-1 receptor agonist

Journal of Psychopharmacology
D FeifelG Melendez

Abstract

Latent inhibition (LI) is a measure of cognitive gating and refers to reduced conditioned learning when there is pre-exposure to the conditioned stimulus (CS) before it is paired with the unconditioned stimulus (US). Dysregulation of LI is associated with some neuropsychiatric disorders, including schizophrenia, and the ability to facilitate LI in rodents is a reasonably good predictive test for antipsychotic drugs. Converging evidence supports neurotensin-1 receptor (NTS1) agonists as novel drugs for schizophrenia. Therefore, we investigated the ability of a brain-penetrating, selective NTS1 agonist, PD149163, to facilitate LI in heterozygous Brattleboro rats, a strain that exhibits naturally low LI. Conditioned taste aversion to flavored water (FW; 0.1% saccharin) was induced by pairing it with malaise-inducing injections of lithium chloride (LiCl). Prior to LiCl-FW pairing, rats received subcutaneous injections of saline, or PD149163 (100 µg/kg or 200 µg/kg). Half the rats in each drug group had been allowed to drink FW the day before the LiCl-FW pairing (pre-exposed rats). Two days after pairing, the amount of FW each rat consumed was recorded. LI, defined as significantly greater FW drinking in the pre-exposed group compar...Continue Reading

References

May 10, 1995·Annals of the New York Academy of Sciences·P D LambertC D Kilts
Jan 1, 1995·Psychological Bulletin·R E Lubow, J C Gewirtz
Jun 20, 1997·Brain Research·D FeifelN R Swerdlow
Feb 10, 2000·Journal of Psychopharmacology·V KumariJ A Gray
Sep 30, 2000·Brain Research. Brain Research Reviews·P C MoserP M Moran
Aug 30, 2001·European Journal of Pharmacology·M BoulesE Richelson
Jan 12, 2002·Current Opinion in Pharmacology·Anne Bérod, William Rostène
May 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Holger RussigJoram Feldon
May 22, 2002·Psychopharmacology·Elisabeth B BinderClinton D Kilts
Mar 26, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David FeifelPaul D Shilling
Sep 30, 2003·Journal of Psychopharmacology·Igor ElmanAlan Breier
Feb 5, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David FeifelPaul D Shilling
Dec 25, 2004·Behavioural Brain Research·Carla BillsAgnes Simonyi
May 11, 2005·Expert Opinion on Investigational Drugs·Mona BoulesElliott Richelson
Aug 23, 2005·Digestive Diseases and Sciences·Jinhong XingEdy Soffer
Jul 29, 2006·Peptides·Jean Mazella, Jean-Pierre Vincent
Dec 7, 2007·Journal of the American Society of Nephrology : JASN·Chunling LiRobert W Schrier
Jun 26, 2008·Pharmacology, Biochemistry, and Behavior·Paul D Shilling, David Feifel
Mar 27, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D FeifelPaul D Shilling
May 15, 2009·Neurobiology of Learning and Memory·A SimonyiT R Schachtman
Oct 6, 2009·Behavioural Brain Research·Siobhan BriodyElliott Richelson
Feb 1, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Elizabeth N HollyAdam J Prus
Apr 6, 2011·Behavioral Neuroscience·David FeifelGilia Melendez
Apr 17, 2012·Behavioural Brain Research·Kristin E SmithElliott Richelson

❮ Previous
Next ❯

Citations

Sep 21, 2019·Annual Review of Pharmacology and Toxicology·Davide Calebiro, Jak Grimes
Dec 4, 2019·Neuroscience and Biobehavioral Reviews·Benjamín RodríguezMirian A F Hayashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here